Agent consensus
HOLD
Multi-agent note output
AMGN
Equity research — AMGN (as of 2026-06-02)
Updated Jun 2, 2026
Coverage
AMGN
Freshness
5 days ago
Market chart
Price context alongside the research narrative.
How the call aged
A simple read on whether this desk view matched what happened in the market over the next 5 trading days, with recent price context from the as-of date.
Desk view: HOLDNot gradedVs peers: Weaker than mostAwaiting market data
Price move
—
2026-06-02 → awaiting data
5-day trend
-2.29%
20-day trend
+2.13%
Recent volatility
+18.61%
Close 328.26 → —
Desk briefing
*May 15, 2026, includes a $2.52 dividend. Prices are unadjusted for dividends.
Full research note
Presentation-ready note with specialist analyst agents, bull and bear agent debate, trader agent synthesis, risk challenge, and portfolio sign-off.
WebserviceX.NET Research Desk
AMGN Equity Research Note
Summary
*May 15, 2026, includes a $2.52 dividend. Prices are unadjusted for dividends.
Bias
HOLD
Horizon
Long-term
Key risk
Event-driven repricing risk if expectations diverge from incoming evidence.
Catalyst watch
EU approval for Imdylltra is the standout positive catalyst — a clinically meaningful label expansion backed by a 40% survival benefit.